Article

Investigation of molecular heterogeneity and new prognostic biomarkers in chronic myeloid leukaemia

2013-01-01

Abstract excerpt

In Chronic Myeloid Leukaemia (CML) tyrosine kinase inhibitor (TKI) therapy has greatly prolonged survival for patients in the chronic phase of CML and is effective also in patients in the accelerated blast phase. However, primary and secondary resistance to TKI remains a significant clinical challenge. Similarly, while a number of additional genetic lesions accompany transformation to the advanced phase, no change...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d0694e7c-62d2-555d-b4fa-e6c3d1e41092
DOI: 10.25560/18677

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Investigation of molecular heterogeneity and new prognostic biomarkers in chronic myeloid leukaemiaDOI 10.25560/18677Read

Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkersSemantic proximity Read

The Biology of CML blast crisis.Semantic proximity Read

Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia.Semantic proximity Read

Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemiaSemantic proximity Read

Prognostic factors in chronic myeloid leukaemia therapySemantic proximity Read

Heterogeneity of molecular markers in chronic myelomonocytic leukemia: a disease associated with several gene alterations.Semantic proximity Read

Analysis of the transcriptome for novel therapeutic targets, and investigation of the role of APOBEC3B in chronic myeloid leukaemia stem cellsSemantic proximity Read

Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia.Semantic proximity Read

The Biology of Chronic Myelogenous Leukemia: Implications for Imatinib TherapySemantic proximity Read

Identification of Prognostic and Susceptibility Markers in Chronic Myeloid Leukemia Using Next Generation Sequencing.Semantic proximity Read

New prognostic factors in chronic myeloid leukaemiaSemantic proximity Read

Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapySemantic proximity Read